2 Information about dapagliflozin

Marketing authorisation indication

2.1 Dapagliflozin (Forxiga, AstraZeneca) is indicated in adults for 'the treatment of symptomatic chronic heart failure'.

2.2 Dapagliflozin is recommended for treating chronic heart failure with reduced ejection fraction in adults (NICE technology appraisal guidance 679).

Dosage in the marketing authorisation

2.3 The dosage schedule is available in the summary of product characteristics for dapagliflozin.


2.4 The list price of 10 mg dapagliflozin is £36.59 per 28‑tablet pack (excluding VAT; BNF online accessed April 2023). The annual treatment cost is £477.30.

  • National Institute for Health and Care Excellence (NICE)